SEQUENT SCIENTIFIC share price has zoomed 7% and is presently trading at Rs 152.5.
Meanwhile, the BSE HEALTHCARE index is at 41,421.4 (up 0.6%).
Among the top gainers in the BSE HEALTHCARE index today are CAPLIN POINT (up 12.8%) and POLY MEDICURE (up 6.0%).
SUVEN PHARMACEUTICALS (down 2.6%) and FORTIS HEALTHCARE (down 2.1%) are among the top losers today.
Over the last one year, SEQUENT SCIENTIFIC has moved up from Rs 89.0 to Rs 152.5, registering a gain of Rs 63.5 (up 71.4%).
On the other hand, the BSE HEALTHCARE index has moved up from 27,819.2 to 41,421.4, registering a gain of 48.9% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were GRANULES INDIA (up 127.6%), Jubilant Pharmova (up 109.2%) and GSK Pharma (up 107.3%).
Must See: These Segments are Witnessing Incredible Growth with Modi's Push
The BSE Sensex is at 80,468.3 .
The top gainers among the BSE Sensex today are Tata Steel (up 1.5%) and NTPC (up 1.1%). The most traded stocks in the BSE Sensex are Tata Steel and NTPC.
In the meantime, NSE Nifty is at 24,575.3 (up 0.1%). Hindalco and BPCL are among the top gainers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 65,401.9 to 80,468.3, registering a gain of 15,066.4 points (up 23.0%).
SEQUENT SCIENTIFIC net profit grew 126.1% YoY to Rs 91 million for the quarter ended June 2024, compared to a loss of Rs 347 million a year ago. Net sales rose 17.1% to Rs 3,902 million during the period as against Rs 3,332 million in April-June 2023.
For the year ended March 2023, SEQUENT SCIENTIFIC reported 372.5% decrease in net profit to Rs -1,220 million compared to net profit of Rs 448 million during FY22. Revenue of the company grew 0.6% to Rs 14,209 million during FY23.
The current Price to earnings ratio of SEQUENT SCIENTIFIC, based on rolling 12 month earnings, stands at 269.4.
Equitymaster requests your view! Post a comment on "SEQUENT SCIENTIFIC Gains 7%; BSE HEALTHCARE Index Up 0.6%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!